[go: up one dir, main page]

WO2011057160A3 - Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120 - Google Patents

Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120 Download PDF

Info

Publication number
WO2011057160A3
WO2011057160A3 PCT/US2010/055747 US2010055747W WO2011057160A3 WO 2011057160 A3 WO2011057160 A3 WO 2011057160A3 US 2010055747 W US2010055747 W US 2010055747W WO 2011057160 A3 WO2011057160 A3 WO 2011057160A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunogenicity
cleavage sites
hiv
vaccine antigens
modification
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2010/055747
Other languages
French (fr)
Other versions
WO2011057160A8 (en
WO2011057160A2 (en
Inventor
Philip Berman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Priority to US13/079,472 priority Critical patent/US9782472B2/en
Publication of WO2011057160A2 publication Critical patent/WO2011057160A2/en
Publication of WO2011057160A8 publication Critical patent/WO2011057160A8/en
Publication of WO2011057160A3 publication Critical patent/WO2011057160A3/en
Anticipated expiration legal-status Critical
Priority to US15/694,388 priority patent/US10201603B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed are novel methods for altering the immunogenicity of vaccine antigens by mutation of cleavage sites recognized by proteases involved in antigen presentation and processing. Also disclosed are therapeutic compositions, vaccines and methods for treating or preventing HIV and other viral diseases.
PCT/US2010/055747 2008-10-04 2010-11-05 Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120 Ceased WO2011057160A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/079,472 US9782472B2 (en) 2008-10-04 2011-04-04 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
US15/694,388 US10201603B2 (en) 2008-10-04 2017-09-01 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25883309P 2009-11-06 2009-11-06
US61/258,833 2009-11-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2010/053637 Continuation-In-Part WO2011050222A2 (en) 2008-10-04 2010-10-22 Therapeutic compositions that disrupt the hydrogen bonded ring structure in gp41 and methods for treating hiv
US13/079,472 Continuation-In-Part US9782472B2 (en) 2008-10-04 2011-04-04 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity

Publications (3)

Publication Number Publication Date
WO2011057160A2 WO2011057160A2 (en) 2011-05-12
WO2011057160A8 WO2011057160A8 (en) 2011-08-18
WO2011057160A3 true WO2011057160A3 (en) 2011-10-27

Family

ID=43970799

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/055747 Ceased WO2011057160A2 (en) 2008-10-04 2010-11-05 Method to improve the immunogenicity of vaccine antigens by modification of cleavage sites in hiv-1 gp 120

Country Status (1)

Country Link
WO (1) WO2011057160A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015084986A1 (en) * 2013-12-03 2015-06-11 The Johns Hopkins University Methods of evaluating immunodominant epitopes
WO2025133250A1 (en) * 2023-12-21 2025-06-26 Universitat Pompeu Fabra Pseudotyped viral like particle for immune cells transduction

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091594A1 (en) * 1999-05-24 2003-05-15 University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US20040191269A1 (en) * 2002-12-03 2004-09-30 Shan Lu Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
US20080032921A1 (en) * 2006-05-18 2008-02-07 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2009121914A1 (en) * 2008-04-02 2009-10-08 Novartis Ag Substituted piperidines as therapeutic compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091594A1 (en) * 1999-05-24 2003-05-15 University Of Pennsylvania CD4-independent HIV envelope proteins as vaccines and therapeutics
US20040191269A1 (en) * 2002-12-03 2004-09-30 Shan Lu Polyvalent, primary HIV-1 glycoprotein DNA vaccines and vaccination methods
US20080032921A1 (en) * 2006-05-18 2008-02-07 Pharmexa Inc. Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions
WO2009121914A1 (en) * 2008-04-02 2009-10-08 Novartis Ag Substituted piperidines as therapeutic compounds

Also Published As

Publication number Publication date
WO2011057160A8 (en) 2011-08-18
WO2011057160A2 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
WO2010019262A3 (en) Polyvalent vaccine
WO2007024941A3 (en) Polyvalent vaccine
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
MX2021006342A (en) Influenza virus mutants and uses therefor.
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
EA201391496A1 (en) IMMUNOGENIC COMPOSITIONS AND METHODS OF APPLICATION OF SUCH COMPOSITIONS FOR INDUCTION OF HUMORAL AND CELLULAR IMMUNE RESPONSE
BR112012033767A2 (en) process for producing a virus of interest, for removing an adventitious agent, and for removing an adventitious agent, virus, and immunogenic composition or vaccine.
WO2013006688A3 (en) N-terminal deleted gp120 immunogens
EP3725328A3 (en) Novel adjuvant compositions
TW200806316A (en) Yeast-based vaccine for inducing an immune response
TW200722101A (en) Novel composition
WO2021154812A8 (en) Coronavirus vaccine formulations
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
CA2817005A1 (en) Rabies glycoprotein virus-like particles (vlps)
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
IN2012DN03209A (en)
EP2358383A4 (en) HIV / VIS VACCINES FOR THE GENERATION OF MUCOUS AND SYSTEMIC IMMUNITY
EA201290956A1 (en) VACCINE AGAINST HIV
WO2014160747A3 (en) Compositions and methods for the treatment or prevention of human immunodeficiency virus infection
MD4608B1 (en) Hyperbaric device and methods for the production of inactivated vaccines and recombinant proteins re-folded / solubilized
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
WO2023102448A3 (en) Coronavirus vaccine formulations
EA033027B1 (en) Attenuated swine influenza vaccines and methods of making and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10829206

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10829206

Country of ref document: EP

Kind code of ref document: A2